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ABSTRACT 
The transcription factor signal transducer and activator of transcription (STAT) 3 is activated 
downstream of cytokines, growth factors and oncogenes to mediate their functions under both 
physiological and pathological conditions. In particular, aberrant/unrestrained STAT3 activity is 
detected in a wide variety of tumors, driving multiple pro-oncogenic functions. For that, STAT3 is 
widely considered as an oncogene and is the object of intense translational studies. One of the 
distinctive features of this factor is however, its ability to elicit different and sometimes contrasting 
effects under different conditions. In particular, STAT3 activities have been shown to be either pro-
oncogenic or tumor-suppressive according to the tumor aetiology/mutational landscape, suggesting 
that the molecular bases underlining its functions are still incompletely understood. Here we discuss 
some of the properties that may provide the bases to explain STAT3 heterogeneous functions, and 
in particular how post-translational modifications contribute shaping its sub-cellular localization 
and activities, the cross talk between these activities and cell metabolic conditions, and finally how 
its functions can control the behaviour of both tumor and tumor microenvironment cell populations. 
 
1. INTRODUCTION 
Signal Transducer and Activator of Transcription (STAT) factors become activated 
downstream of both extrinsic and intrinsic signals by phosphorylation on a conserved tyrosine 
residue mainly accomplished by receptor-associated JAK kinases [1, 2]. Tyrosine-phosphorylated 
(YP)-STATs form active dimers that concentrate in the nucleus to regulate the expression of target 
genes [3]. The family member STAT3 is canonically activated by YP downstream of numerous 
cytokines, growth factors and oncogenes, and is accordingly constitutively active in a high 
percentage of tumors and tumor-derived cell lines of both liquid and solid origin, which often 
become STAT3 addicted (recently reviewed by [4, 5]). Thus, STAT3 is widely considered as an 
oncogene and a good target for anti-cancer therapy. In keeping with the wide repertoire of distinct 
target genes activated in different contexts, STAT3 was reported to exert a plethora of different 
functions in normal as well as in transformed cells. STAT3 constitutive activity in tumours can 
promote cell survival and proliferation, down-modulate anti-tumour immune responses and promote 
tumor angiogenesis, enhance tumour invasion and metastasis by inducing epithelial to 
mesenchymal transition (EMT), alter the extracellular matrix through the expression of matrix 
metalloproteinases (MMP) and the enhancement of collagen cross-linking and tissue tension, 
modify cell energy metabolism and mitochondrial activity. Finally, STAT3 activity can confer 
tumor-initiating features to cancer cells in a number of solid tumors [4, 6-9].  
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 Not surprisingly therefore, STAT3 transcriptional functions are required for cellular 
transformation downstream of several oncogenes that trigger its phosphorylation on Y705 such as, 
for example, Src [10]. However, STAT3 is also required for Ras-mediated tumor transformation, 
for which YP and transcriptional activities are dispensable [11], suggesting that both transcriptional 
and non-transcriptional activities of STAT3 promote tumorigenesis. Despite this knowledge, and 
the wealth of data supporting the concept of STAT3 as an oncogene, several reports have now 
highlighted its ability to suppress tumor onset and/or progression.  
 
2. STAT3 the oncogene or STAT3 the oncosuppressor? 
The first indication that STAT3 tumor-promoting functions may be strongly context-
dependent came from the observation that STAT3 plays a dual role in glioblastoma, and this role 
depends on its mutational status. While in the context of tumors driven by the type III epidermal 
growth factor receptor (EGFRvIII) mutation STAT3 triggered glial transformation by associating 
with the mutant receptor in the nucleus, in the context of PTEN loss STAT3 inhibited glial tumor 
transformation and growth [12]. Indeed, the analysis of clinical samples showed that PTEN loss and 
EGFRvIII expression define distinct glioblastoma subsets, with down-regulation of STAT3 
signaling only associated with the subset demonstrating PTEN loss.  Also, in the context of a PTEN 
-loss driven mouse model of prostate cancer, STAT3 ablation accelerated metastatic progression by 
down-modulating p19ARF to bypass senescence [13]. Clinically, reduced IL-6 and STAT3 
expression correlated with increased risk of recurrence in prostate cancer patients.  
The mutational landscape also appears to determine the role of STAT3 in lung cancer. 
Indeed, despite a host of literature supporting a pro-oncogenic role of STAT3 in lung cancer, 
particularly in the context of EGFR driver mutations, Casanova and co-authors have recently shown 
that STAT3 exerts a tumor suppressive role in KRAS mutant lung adenocarcinomas, by impairing 
NF-kB-mediated IL-8 expression, tumor myeloid cell recruitment and vascularization [14]. Indeed, 
the authors could demonstrate that low STAT3 levels correlate with increased malignant 
progression and poor prognosis in adenocarcinoma patients with KRAS mutation and/or with a 
smoking history, highlighting how tumor stratification according to mutational status and clinical 
history may be crucial to determine the involvement of specific signaling pathways.  
 In the context of colon cancer the etiology also appears to strongly influence STAT3 
involvement. While the relevance of the IL-6-STAT3 pathway in promoting inflammation-driven 
colorectal tumorigenesis is well-documented [15, 16], Stat3 gene inactivation delayed tumor onset 
in the ApcMin mouse model of intestinal cancer, while promoting faster progression of more 
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invasive tumors, via transcriptional regulation of the adhesion molecule CEACAM1 and 
modulation of Snail1 degradation and EMT [17, 18] .  
Finally, in human primary papillary thyroid carcinoma, an inverse relationship was observed 
between YP-STAT3 and tumor size/metastasis. Accordingly, STAT3 deficiency in a thyroid 
carcinoma model enhanced tumor cell proliferation, partly by down regulating the tumor suppressor 
IGFBP7 [19].  
Certainly, these contrasting actions can be partly explained by STAT3 ability to activate a 
wide variety of target genes depending on cell type and conditions, which in turn is determined by 
cell-specific accessibility of genomic STAT3 binding sites, cell- and signal-specific interactions 
with distinct co-factors, and STAT3’s ability to activate transcription by interacting with other 
transcription factors, modulating or redirecting their activity (see [4, 20] for recent reviews). Other 
important features influencing STAT3 multifaceted functions are (i) the multiple modifications 
affecting STAT3 activities/functions that result in many functionally distinct forms of this factor 
modulating both transcriptional and non-transcriptional activities in different sub-cellular 
compartments including the nucleus, the cytoplasm or the mitochondrion (Fig. 1); (ii) the reciprocal 
cross-talk that exists between STAT3’s multiple activities and the metabolic and redox states, and 
(iii) the increasing knowledge that STAT3 is profoundly involved in mediating both cell 
autonomous and non-cell autonomous functions in tumor cells and tumor stromal components, with 
both coherent and incoherent effects. 
Since the multiple roles of STAT3 in tumors have been extensively described in many 
excellent recent reviews [4, 5, 20, 21], here we will concentrate on discussing some of these aspects 
and how they may affect the multitude of apparently contrasting STAT3 biological functions. 
 
3. Post-translational modifications: how many STAT3s  are there?  
3.1. Tyrosine phosphorylation 
As mentioned in the introduction, STAT3 canonical activity as a transcription factor mainly 
depends on JAK kinase-mediated phosphorylation on Y705 (YP), which endows STAT3 dimers 
with the ability to concentrate in the nucleus, bind to DNA and activate transcription. Upstream 
signals that can trigger STAT3 YP range from cytokines of the IL-6 family, leptin, IL-12, IL-17, 
IL-10, Interferons, growth factors such as G-CSF, EGF, PDGF, and a number of oncogenes, the 
prototype of which are Src family kinases but also including Abl, Sis, Fps, Ros, Met and ErbB2	 [5, 
22, 23]. Recently, G protein coupled receptors, like the sphingosine-1-phosphate receptor (S1PR)1, 
and several Toll like receptors have been shown to activate STAT3 (for recent reviews, see [4, 5]). 
In particular, S1PR1 overexpression has been linked to the maintenance of constitutive STAT3 
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activity [24]. This vast collection of potential activators offers a glimpse of the variety of conditions 
that can lead to both physiological and aberrant STAT3 activity. 
Under physiological conditions, STAT3 activation is tightly controlled by negative regulators, 
which mainly fall into three groups: phosphatases, Suppressor Of Cytokine Signaling (SOCS) 
proteins, and Protein Inhibitor of Activated STAT (PIAS) proteins [25-27]. Phosphatases like SHP-
1, SHP-2, PTP1B or T cell PTP terminate STAT3 activation, acting either at the level of JAK 
kinases or directly in the nucleus [25]. Among SOCS proteins, SOCS3 is a primary transcriptional 
target of STAT3 and acts as a negative feedback regulator to inhibit JAK activity [28]. Finally, 
PIAS3 prevents the binding of STAT3 to its target DNA sequence [29]. Persistent STAT3 
activation in tumors is known to occur downstream of aberrant upstream stimulation [30], as a 
result of impaired negative regulation [31] and upon cadherin-mediated cell-cell contacts [32]. 
More recently, trans-activating STAT3 somatic mutations have been shown to play a role in the 
pathogenesis of hepatic and hematopoietic malignancies [33-36]. Additionally, un-phosphorylated 
STAT3 is also thought to be involved in transcriptional regulation, being able to translocate to the 
nucleus, bind DNA both directly and indirectly, and activate transcription of target genes including 
several oncogenes	 [37-39]. Indeed, high levels of nuclear un-phosphorylated STAT3 correlate with 
a bad prognosis in glioblastoma	[40]. 
3.2. Serine phosphorylation.  
In addition to YP, STAT3 can undergo several other post-translational modifications, most 
of which have been correlated with enhanced trans-activating potential. Phosphorylation on serine 
residue 727 (SP) within the carboxy-terminal transcription activation domain can be carried out by 
several kinases including MAP kinases and mTOR, downstream of both classical STAT3 activating 
cytokines/growth factors and of Ras proteins [41, 42]. Although SP is required for optimal 
induction of a subset of target genes [43], SP-STAT3 appears to mostly function independently of 
YP in the mitochondrion (see below). Phosphatases leading to S727 dephosphorylation have not 
been characterized yet. Incidentally, an alternatively spliced form of STAT3, STAT3beta, which 
lacks S727, is specifically up regulated under inflammatory conditions and regulates an only 
partially overlapping subset of STAT3 target genes [44, 45]. 
3.3. Acetylation.  
STAT3 is also known to be acetylated (Ac) on multiple lysine (K) residues by the CBP/p300 
histone acetyltransferase in response to cytokines and growth factor signaling. Acetylation on K685 
enhances tyrosine phosphorylation, dimer stability and transcriptional activity [46], leading to DNA 
methylation and silencing of tumor suppressor genes through recruitment of DNA 
methyltransferase 1 [47]. Deacetylation can be brought about by the NAD-dependent silent 
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information regulator protein (SIRT) 1, which is activated under starvation conditions [48]. SIRT1-
mediated deacetylation leads to both reduced YP and transcriptional activity and decreased SP-
STAT3 mitochondrial localization, likely in an indirect way [49]. In contrast, K87 acetylation 
downstream of insulin stimulation was recently shown to specifically promote STAT3 
mitochondrial translocation and functions [50].  
3.4. Methylation.  
Nuclear STAT3 can be methylated on several residues, with contrasting effects on its activities. 
The histone methyltransferase SET9 can methylate promoter-bound STAT3 on K140, impairing 
transcription of its target genes [51]. In contrast, K180 tri-methylation by the EZH2 component of 
the Polycomb Complex 2 is required for STAT3 YP and transcriptional activity in glioblastoma and 
prostate cancer cells [52].  
3.5. Oxidation, glutathionylation.  
Finally, STAT3 transcriptional activity can be differentially modulated under conditions of 
oxidative stress and cytokine signaling, via the oxidation or glutathionylation of multiple cysteine 
residues, establishing a crucial cross-talk between cell metabolic conditions and STAT3 functions 
[53-56]. At present, the influence of these modifications on the activity of the other STAT3 
modifications is unknown. 
 
The interplay between these multiple functionally distinct STAT3 forms, whose relative levels, 
localization and activities are reciprocally regulated by multiple signals and by specific metabolic 
conditions sets the stage for addressing the complexity of the STAT3 functions. 
 
4. STAT3 and energy metabolism: of electron transport complexes and transcription  
Energy metabolism plays a central role in tumor progression, with tumor cells often 
undergoing a metabolic switch known as the Warburg effect, leading to increased aerobic 
glycolysis and reduced mitochondrial activity [57]. STAT3 is an important player in this switch, 
since its constitutive transcriptional activity promotes aerobic glycolysis and down regulates 
mitochondrial activity by inducing HIF1a transcription while reducing the expression of electron 
transport complexes (ETC) [58]. In turn, this metabolic switch leads to enhanced production of 
lactate and decreased production of ROS, which contribute to protect cells from apoptosis and 
senescence. Intriguingly, STAT3 has been shown to regulate mitochondrial activities in a 
completely different fashion, via its localization to this organelle, as observed in a number of cell 
types and tissues [11, 59-62]. In keeping with its association with distinct ETCs [59, 63], protease 
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experiments demonstrated that, despite the lack of a mitochondrial targeting sequence, STAT3 is 
associated with the inner mitochondrial membrane [63]. STAT3 mitochondrial import can be 
chaperoned by the ETC I component Gene associated with Retinoid Interferon induced cell 
Mortality (GRIM) 19 [63], and by the heat shock protein 22, at least in cardiomyocytes [64].  
Like nuclear STAT3, mitochondrial STAT3 acts as a pro-survival factor that enhances cell 
fitness under specific stress conditions such as heart ischemia or Ras-mediated transformation [11, 
59, 65]. It has been shown to preserve optimal ETC activity, increasing mitochondrial membrane 
polarization and ATP production, and to enhance lactate dehydrogenase activity while at the same 
time reducing ROS production, possibly via the interaction with ETC I and II [59, 63, 65-68]. 
Protection from apoptosis may also stem from its ability to inhibit the opening of the mitochondrial 
permeability transition pore by interacting with cyclophilin D [69]. The association between 
increased ETC activity and reduced production of ROS mediated by mitochondrial STAT3, which 
was confirmed in many cell types including astrocytes, hematopoietic stem cells and activated 
CD4+ T lymphocytes [60-62], is in apparent contrast with the knowledge that ETC activity is the 
main source of ROS. A fascinating explanation has been proposed by Rincon and colleagues, who 
demonstrated that IL-6-induced CD4+ T cell activation occurs via mitochondrial STAT3 and 
correlates with the formation of ET super complexes, known to minimize electron leakage [62]. In 
this context, ETC activity increased mitochondrial membrane polarization and raised the levels of 
mitochondrial Ca2+ . Mitochondrial STAT3 can contribute to the control of ROS levels also by 
indirectly inducing, via an unknown mechanism, the synthesis of the major cellular ROS scavenger 
glutathione [70].  
SP, but not YP, is believed to be required for most, if not all, STAT3 mitochondrial 
functions, and can be elicited by MAP kinases downstream of Ras stimulation [11, 71], and by 
PKCe in keratinocytes upon TPA or EGF treatment [68, 72]. Recently however, it was proposed 
that STAT3 acetylation on lysine residue 87, occurring downstream of insulin signaling, is the 
modification required for STAT3 to translocate to mitochondria, where it increases mitochondrial 
membrane potential and ATP production by interacting with pyruvate dehydrogenase complex E1 
[50]. While the assessment of how acetylation levels of mitochondrial STAT3 may affect its 
functions needs to be systematically addressed, it is already evident that SP is not required for 
mitochondrial import, and that YP STAT3 is abundantly detected within mitochondria [62, 68, 72]. 
Intriguingly, overexpression of BCL2 in the human colon cancer cell line HCT116 was shown to 
recruit YP, not SP, STAT3 to mitochondria, leading to increased •O2- production and enhanced 
survival [73]. Additionally, mitochondrial fractions from both activated CD4+ T cells and LIF-
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stimulated ES cells appear to be enriched in YP STAT3 [62, 68]. At present, whether mitochondrial 
STAT3 is phosphorylated on both Y and S or whether YP and SP STAT3 represent two distinct 
pools is unknown. At any rate, transcriptionally active STAT3 is likely to play a specific role in 
mitochondria, as suggested by its ability to bind to mitochondrial DNA in both keratinocytes and 
ESCs. In keratinocytes, STAT3 interacts with the mitochondrial transcription factor TFAM to 
down-regulate respiratory chain genes [72], leading to reduced ETC activity. In contrast, in ES cells 
it acts as a transcriptional activator of ETC subunits, leading to increased complexes assembly and 
enhanced respiratory activity, which is required to promote high proliferative activity downstream 
of LIF [68]. Although the specific role for S or Y phosphorylation has not been addressed in these 
contexts, the ability of mitochondrial STAT3 to bind to DNA and the detection of dimeric 
mitochondrial STAT3 are suggestive of YP STAT3 being involved in these functions	[72].  
 A host of observations supports the idea that several known STAT3 pro-oncogenic activities 
involve the SP, rather than the YP protein. Indeed, H-RAS driven transformation of MEF cells, K-
RAS-driven myeloid malignancy, and pancreatic cancer development driven by Receptor for 
Advanced Glycation Endproducts (RAGE)-dependent IL-6 signaling were all shown to be 
dependent on the mitochondrial activities of SP STAT3 that enhance ETC activity, mitochondrial 
membrane polarization and ATP production [11, 66, 71, 74]. Moreover, SP STAT3 mediates tumor 
growth and metastatic potential of mammary 4T1 mouse tumor cells via increased complex I 
coupling and reduced ROS production [67]. Accordingly, decreased STAT3 mitochondrial 
localization triggered by phospho-valproic acid treatment results in reduced growth of human 
pancreatic tumor xenografts [75]. Interestingly, expression of the FGFR-R388 single nucleotide 
polymorphism in pituitary cells leads to SP-STAT3 accumulation in mitochondria, correlating with 
enhanced cytochrome c oxidase activity and pituitary tumorigenesis [76].  
 
5. STAT3 and redox balance: to be or not to be (oxidized) 
Redox homeostasis is maintained thanks to an equilibrium between ROS production and 
scavenging, whose disruption may result in oxidative stress which in turn contributes to the 
pathogenesis of cancer, neurodegeneration and aging [77]. While controlled ROS production is 
involved in the signaling of growth factor and cytokine receptors, an excess of ROS can directly 
lead to oxidation-mediated inactivation of several protein phosphatases, indirectly activating key 
proliferation and survival signaling pathways. Thus, a correct balance between functional and toxic 
effects of ROS is crucial for cell survival and proliferation [77]. 
STAT3 contributes to intracellular ROS homeostasis in a number of ways. As discussed 
above, under different cellular contexts both nuclear and mitochondrial STAT3 can lead to reduced 
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production of ROS and increased ROS scavenging [11, 58, 70]. On the other hand, STAT3 activity 
itself is affected by ROS concentration. Oxidation and glutathionylation of specific Cys residues 
under conditions of oxidative stress impair STAT3 DNA binding and transcriptional activity [53-
56], while mild ROS production downstream of IGF1, EGF and other growth factor signaling can 
actually enhance STAT3 YP and nuclear activity [78-81]. Similarly, starvation-induced ROS leads 
to increased YP STAT3 binding to the IL-6 promoter during autophagy in HeLa cells [82].  
STAT3 oxidation appears to be part of a redox relay for ROS signaling downstream of the 
thiol peroxidase peroxiredoxin-2 (Prx2), one of the major H2O2 scavengers within the cell. Upon 
H2O2 treatment, Prx2 transfers oxidative equivalents to Cys residues within the STAT3 DNA 
binding and transcriptional activation domains, attenuating transcriptional activity [56]. 
Importantly, Prx2-mediated STAT3 oxidation is also involved in modulating STAT3-mediated 
transcription downstream of IL-6-type cytokines, as the expression of a redox-insensitive cysteine 
mutant STAT3 leads to increased STAT3 activity and cell growth rates. This cross-talk between 
oxidative and non-oxidative STAT3 modifications can integrate exogenous and endogenous H2O2 
levels and cytokine signaling, affecting the levels, localization and activities of the different forms 
of STAT3 to control intracellular redox homeostasis as well as cell proliferation and survival. This 
may be particularly relevant for cancer cells, which often rely on high levels of ROS to promote 
proliferation, survival and metabolic adaptation, thus depending heavily on efficient antioxidant 
activities to prevent oxidative stress and apoptosis [83]. 
 
6. STAT3 as an autophagy regulator: to eat or not to eat (itself) 
Autophagy, and in particular macro-autophagy, is a cellular process that delivers 
cytoplasmic material to lysosomes for degradation [84], and it plays ambiguous roles in tumor 
transformation and progression [85]. While an efficient autophagy machinery is essential to protect 
cells from transformation, cancer cells rely on autophagy for their survival and diffusion. Thus, 
fine-tuning of the autophagy process may represent an appealing strategy for both prevention and 
therapy of cancer. The knowledge that STAT3 can both promote and inhibit autophagy adds a 
further layer of complexity to the functions of this factor in tumorigenesis (recently reviewed in 
[86]). 
 STAT3 can inhibit autophagy both from the nucleus and the cytoplasm. Nuclear YP-STAT3 
can control the levels and activity of beclin1, an essential autophagy player that is often down-
regulated in cancer, both directly by repressing its transcription [87] and indirectly by inducing the 
beclin1 negative regulators BCL2 and MCL1 [88, 89], or miRNA17, which targets both Beclin1 
and  ATG7, another essential component of the autophagy pathway [90, 91]. miR17 down-
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regulation was shown to promote autophagy and to increase the sensitivity of cancer cells to 
chemotherapy [92, 93]. 
From within the cytoplasm, STAT3 was proposed to inhibit autophagy by interacting with 
protein kinase R, blocking its enzymatic activity [94]. Fatty acids like palmitate trigger STAT3 
dissociation from PKR leading to stimulation of the autophagy flux [94, 95]. In addition, un-
phosphorylated STAT3 was shown to inhibit FOXO-mediated induction of several autophagy 
related genes by maintaining FOXO1 and FOXO3 in the cytoplasm of T cells [96, 97]. Finally, SP 
STAT3 has been shown to inhibit autophagy downstream of mTOR [98]. 
STAT3 pro-autophagy effects are less direct and strongly linked to hypoxia-related 
response. STAT3 and HIF1a are connected by a feed-forward loop whereby active YP-STAT3 
increases the levels of HIF1a, which in turn helps to maintain STAT3 activation via PKM2-
mediated YP [99]. Hypoxic conditions are known to promote HIF1a-dependent autophagy 
activation, which allows cells to survive during prolonged hypoxia by limiting ROS accumulation, 
and may well involve STAT3 transcriptional activity [100]. Accordingly, hypoxia was reported to 
drive STAT3 and HIF1a-dependent autophagy, impairing the susceptibility of tumor cells to CTL-
mediated cell lysis [101]. In this context however, STAT3 activation was not implicated in 
autophagy induction, but rather occurred downstream of autophagy-mediated Src activity [102].  
Additionally, in glioblastoma cells hypoxia-induced IL-6 was shown to activate autophagy via 
STAT3-dependent indirect up-regulation of ATG5 [103].  
STAT3 can also induce autophagy independently of hypoxia. For example, EGFR/STAT3 
signaling is crucial to promote autophagy and maintain the tumor-initiating potential of breast 
cancer stem cells in MMTV-PyMT mouse mammary tumors [104]. Finally, mitochondrial STAT3 
activities have been implicated in mediating RAGE-induced autophagy that is involved in the 
development of early pancreatic cancer lesions [66]. Along these lines, it is also interesting to note 
that activated Ras, which relies on SP-STAT3 for tumor transformation, requires autophagy to 
maintain oxidative metabolism and cell viability, suggesting a potential connection to mitochondrial 
STAT3 [105]. 
Thus, multiple STAT3 activities, specific post-translational modifications and orchestrated 
sub-cellular localization are involved in fine-tuning autophagy under both physiological and 
pathological conditions, contributing to STAT3’s double-edged functions in tumorigenesis. 
 
7. Both seed and soil: STAT3 and the tumor microenvironment 
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Tumor growth relies on the establishment of reciprocal relationships with components of the 
tumor microenvironment (TME), which is composed of cells of hematopoietic and mesenchymal 
origin. TME cell components can be either stromal resident cells or be specifically recruited to the 
tumor site, where they are instructed by cancer cells to acquire pro-tumorigenic features [106]. The 
reciprocal crosstalk among different cell types is responsible for the establishment and maintenance 
of the pro-oncogenic niche, primarily initiated by cancer cells and relying on cell-cell contacts as 
well as on a complex network of released cytokines, chemokines and growth factors. Tumor-
associated macrophages (TAMs) or cancer associated fibroblasts (CAFs), for instance, acquire the 
ability to suppress immune responses as well as supporting EMT, angiogenesis, extracellular cell 
matrix remodeling and chemo resistance [107, 108], while immune-suppressive cells such as 
myeloid-derived suppressor cells (MDSCs) or regulatory T cells (Treg) become aberrantly recruited 
to the TME to facilitate tumor immune escape [109-111]. 
Several lines of evidence suggest that the IL-6/STAT3 pathway is strongly involved in 
mediating the cross talk between tumor and TME cells. Indeed, both cancer and stromal cells often 
secrete IL-6 or other STAT3-activating cytokines/growth factors, initiating a feed forward loop that 
supports continued STAT3 activity (reviewed in [6, 112]).  
In their seminal 2004 paper, Wang et al. reported that constitutive STAT3 activation in 
cancer cells favors the expression of soluble factors that in turn activate STAT3 in antigen-
presenting cells, blocking dendritic cell (DC)-mediated T cell activation. Indeed, STAT3 inhibition 
in tumor cells increased the secretion of pro-inflammatory cytokines, activating dendritic cells to 
induce tumor-specific T-cell responses [113, 114]. Accordingly, STAT3 inactivation in the 
hematopoietic compartment triggered immune-mediated inhibition of tumor growth and metastasis 
via the coordinated activation of DCs, T cells, natural killer (NK) cells and neutrophils [115]. Many 
reports have since confirmed and extended these initial findings in a number of TME cell types and 
tumor models, as summarized below. Accordingly, in vivo efficacy of STAT3 inhibitors often 
involves modulation of both cancer and TME cell functions [116-118].  
7.1 Myeloid Derived Suppressive Cells (MDSC) and T regulatory cells (Treg) 
STAT3 activity has been directly linked to the immunosuppressive functions of Treg and 
MDSC cells. For example, STAT3 inhibition could block tumor growth both directly, interfering 
with proliferation of ovarian and pancreatic tumor cells, and indirectly by impairing IL-6 secretion, 
resulting in reduced numbers of infiltrating MDSC and pro-tumorigenic T cells, as shown by using 
xenograft tumor models [117, 118]. Accordingly, myeloid STAT3 enhanced the suppressive 
activity of MDSCs suppressing anti-tumor T cell responses to accelerate the progression of a 
number of solid tumors [119-121]. Of note, within the same ApcMin colon tumor model, the pro-
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oncogenic activity of myeloid STAT3 contrasted with the tumor suppressor activity of epithelial 
STAT3 [17]. Finally, in the context of KRAS-driven lung tumorigenesis, blockade of the IL-
6/STAT3 pathway impaired tumor progression by decreasing the number of Treg’s and MDSC cells 
in the TME [122]. Similarly, in the TRAMP murine prostate cancer model, depletion of the STAT3 
negative feedback regulator SOCS3 in myeloid cells lead to STAT3-dependent MDSC expansion, 
enhancing TME immunosuppressive functions and tumor growth [123]. Notably, STAT3 activation 
in MDSCs was also required for cancer stem cell proliferation in a pancreatic cancer model [124]. 
Finally, Sorafenib-mediated STAT3 inhibition upon CD8+ T cell adoptive transfer impaired Treg 
and MDSC recruitment to the TME through the down-regulation of immunosuppressive factors, 
thus unleashing CD8+ T cell responses [125]. 
Additionally, STAT3 activity in MDSCs, and more in general in myeloid cells, has been 
linked to metastasis and radioresistance. Hua Yu and collaborators showed that the S1PR1-STAT3 
axis is crucial for myeloid cells ability to condition the pre-metastatic niche [126], and to trigger 
Treg accumulation within the tumor [127]. Accordingly, STAT3 activation in tumor-free lymph 
nodes positively correlated with the number of premetastatic niches and was predictive of poor 
survival in patients with several types of cancer [126, 128, 129]. Additionally, high YP STAT3 
levels in murine melanoma myeloid cells inversely correlated with the ability of CD8+ T cells to 
control metastatic colonization by inhibiting myeloid cell expansion [130]. Indeed, breast cancer 
cells and MDSCs form a synergistic feedback loop based on IL-6/sIL-6R secretion and STAT3 
activation, leading to increased MDSC recruitment and enhanced metastatic potential [131]. 
Finally, TLR9-mediated activation of the IL-6/STAT3 loop by radiotherapy in myeloid cells 
enhances MDSCs tumor-suppressive activities, thus promoting recurrence in several solid tumors 
[132].  
7.2. Tumor associated macrophages (TAMs). 
STAT3 activation in tumor-associated macrophages (TAMs) has also been associated with 
their acquirement of pro-tumorigenic features. In a rat model of breast cancer, STAT3 inhibition 
could revert a TAM immune suppressing phenotype leading to immune-mediated inhibition of 
tumor growth [133], and STAT3 was shown to promote pro-tumorigenic M2 polarization of TAMs 
in glioma, enhancing proliferation and angiogenesis [134]. This activity may be due to STAT3-
mediated expression of the B7-H4 T-cell co-inhibitory molecule that impairs CD8+ T cell activation 
[135]. Accordingly, endostatin expression could skew TAM polarization towards an M1 phenotype 
both by inverting the ratio between phophorylated STAT3 and STAT1 and by stimulating NF-kB 
activity, resulting in the inhibition of 4T1 breast tumors in syngeneic mice [136].   
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Recent findings, however, challenge the simplistic vision of STAT3 being purely pro-
tumorigenic in tumor associated myeloid cells, arguing for a more complex role in orchestrating 
their expansion and activities. For example, in contrast to what has been observed in the TRAMP 
model, myeloid SOCS3 deletion resulted in impaired glioma progression by sustaining both STAT3 
and  STAT1, activity, correlating with M1 polarization of TAMs and reciprocal changes in Treg 
and CD8+ CTL cells [137]. In the same vein, STAT3 could promote the expansion of monocyte-
derived MDSC in peripheral lymphoid organs, but their differentiation into tumor-promoting TAMs 
required subsequent STAT3 inactivation, which was mediated by CD45 in the hypoxic tumor 
environment [138]. 
7.3. Anti-tumoral T lymphocytes 
STAT3 activity can also directly inhibit anti-tumorigenic T cell functions. NK cell activities 
can be blunted by STAT3 activation, as shown in an IL-6-secreting neuroblastoma model [139]. 
Accordingly, STAT3 inhibition allowed efficient expansion and tumor infiltration of adoptively 
transferred CD8+ T cells, eliciting strong antigen-specific T cell responses and immune clearance in 
various models of solid tumors [140, 141]. Thus, STAT3 inhibition might improve the efficacy of T 
cell adoptive transfer therapies. 
7.4. Cancer Associated Fibroblasts (CAF) 
The cross talk between cancer cells and CAFs also heavily relies on the activation of the IL-
6-STAT3 pathway in both CAFs and tumor cells. Indeed, STAT3 activation elicited by cell-cell 
contacts, by the activation of the fibroblast activating protein (FAP), or by the secretion of STAT3-
activating soluble factors such as IL-6 or LIF by cancer cells was shown to be essential to elicit 
activation of CAFs and pro-tumoral activities in head and neck, lung, breast, gastric or pancreatic 
cancer [142-146]. STAT3-mediated pro-tumorigenic activities ranged from CCL2 secretion for 
MDSC recruitment [147], to Twist1 up-regulation for the induction of cancer cell movement and 
invasion [144], to the induction of an epigenetic switch leading to methylation–mediated silencing 
of the SHP1 gene and consequent constitutive activity of JAK1 [145]. Similarly, direct contact with 
pancreatic cancer cells could elicit methylation-dependent SOCS1 silencing, leading to constitutive 
STAT3 YP [146].  
On the other hand, CAFs can promote and sustain STAT3 activation in cancer cells, with all 
its multifaceted functions, via secretion of IL-6 or other STAT3-activating gp130-family cytokines 
in various carcinoma models such as breast, colorectal, lung, pancreas, liver and endometrial cancer 
[143, 145, 148-151]. Further, CAF-secreted IL-6 can also activate STAT3 in DCs to elicit the 
differentiation of an immune-suppressive regulatory DC subset [152].  
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The observed multiple pro-oncogenic activities of STAT3 in both tumor and TME cells may 
help explain the widespread contributions of this factor to tumor onset, progression and metastasis, 
and fuel the interest in developing STAT3 inhibitors whose in vivo efficacy may be enhanced by the 
numerous cell types involved. In this vein, the novel dual inhibitor NT157, which promotes the 
inactivation of both the IGF1R and STAT3 pathways, was shown to impair tumor progression in 
the ApcMin mouse model of colorectal cancer, acting on cancer cells, CAFs and TAMs to down-
regulate the expression of several immune-suppressive secreted factors including TGFb, IL-6 and 
IL-10 [150]. 
 
8. CONCLUDING REMARKS 
Despite the concept of oncogenic STAT3 being widely accepted, an increasing body of data 
now supports the view that STAT3 functions are too variegated to be easily classified. Ultimately, 
the specific cellular role of STAT3 is determined by the integration of multiple signals that dictate 
the overall abundance of its many differentially modified forms, and consequently their sub-cellular 
localization and activity (see Figure 1). Direct modulation by oxidation suggests that the effects of 
upstream signals will be further modified by cell metabolic conditions, including oxidative stress 
and autophagy activation. Enhanced mitochondrial activities by SP STAT3 may be required for cell 
transformation downstream of certain oncogenes such as Ras, but be detrimental in tumors types 
requiring the establishment of a Warburg effect. STAT3 pro- or anti-autophagy activities may either 
favor or contrast tumor cell transformation and progression, depending on the specific tumor type, 
stage and metabolic conditions. Finally, pro-tumoral or onco-suppressive STAT3 activities will be 
determined, in each specific case, by the actions exerted by the known differentially modified 
STAT3s on both cancer and TME cells, whose effects are not always coherent. 
Based on these considerations, the potential outcome of therapies based on STAT3 
inhibition need to be tailored to the specific tumor type and mutational landscape, and directed 
against specific STAT3 modifications. This stresses the need for a systematic assessment of STAT3 
activities in specific tumors, downstream of distinct oncogenic pathways, and in cancer or TME 
cells, whose interconnections need to be studied in immuno-competent in vivo models. In turn, this 
new knowledge will help define specific and effective inhibition strategies, as well as establish 
guidelines to assess treatment outcomes. 
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Figure 1 
 
 
 
FIGURE LEGEND 
Figure 1. Main STAT3 activating pathways and their induced post-translational 
modifications.  
The scheme depicts the main STAT3 post-translational modifications, together with their known 
biological effects and upstream regulators.  
TKR, tyrosine kinase receptors; SFK, Src family tyrosine kinases; GPCRs, G protein coupled 
receptors; TLR, toll-like receptors. 
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